Stock exchanges & markets

Overview Watchlists

Novartis wins EU approval for Cosentyx in polymyalgia rheumatica

21. Oct 2026

(AWP Alliance News) - Novartis received European Commission approval for Cosentyx to treat adults with polymyalgia rheumatica who respond inadequately to glucocorticoids or relapse during tapering. The drug doubled sustained remission rates versus placebo at Week 52 in a Phase III trial.

Regulatory reviews for the indication remain ongoing in the US and Japan.

https://www.globenewswire.com/NewsRoom/ReleaseNg/402530901

Disclaimer: This news brief was created using generative artificial intelligence. Novartis AG published the original content used to generate this news brief via GlobeNewswire on October 21, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now